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Abstract
Rheumatoid arthritis is a systemic autoimmune disease characterized
by chronic, destructive, debilitating arthritis. Its etiology is unknown;
it is presumed that environmental factors trigger development in
the genetically predisposed. Epstein–Barr virus, a nearly ubiquitous
virus in the human population, has generated great interest as a
potential trigger. This virus stimulates polyclonal lymphocyte
expansion and persists within B lymphocytes for the host’s life,
inhibited from reactivating by the immune response. In latent and
replicating forms, it has immunomodulating actions that could play
a role in the development of this autoimmune disease. The evidence
linking Epstein–Barr virus and rheumatoid arthritis is reviewed.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
polyarthritis that progressively destroys synovial joints and
can cause systemic complications. RA affects about 1% of
the world’s population [1], and its prevalence in women is
twofold to fourfold that in men [2,3]. RA has enormous
personal, social, and economic impact [4,5]; women with RA
have overall mortality rates 2.3-fold those in age-matched
controls [6]. New biologic therapies, based on an increasing
understanding of the molecular mechanisms involved in RA,
afford a more normal life to many, but the burden of disease
remains high. At present there is no known cure. Despite
improved therapy, the long-term prognosis remains poor and
average life expectancy is reduced by 3 to 18 years [7]. Both
the direct costs of treatment of RA and the indirect costs of
disability and loss from the workplace are high [8,9].
RA is marked by extensive synovial hyperplasia and infiltration
by lymphocytes, monocytes, macrophages, and fibroblasts.
RA is a predominantly CD4+ T helper type 1 (Th1)-driven
disease [10]. Aberrant T cell activation is one of the earliest
events in the development of RA, with CD4+ T cells
stimulating monocytes and macrophages to produce
inflammatory cytokines, including interleukin (IL)-1, IL-6, and
tumor necrosis factor-α (TNF-α), as well as proteolytic
enzymes, destroying synovium, cartilage, and underlying bone
[11]. The T cells infiltrating the rheumatoid synovium are
oligoclonal, implicating an antigen-driven process [12,13],
but the inciting antigen or antigens remain unidentified.
Activated T cells also signal B cells to produce increased
levels of immunoglobulins, including rheumatoid factor (RF).
Autoreactive B cells also have a central role in the
development of RA, producing autoantibodies that might be
involved in tissue damage in RA [14].
Genetic factors are important in disease susceptibility, but
environmental exposures are probably crucial as well. Many
exposures have been investigated as possible risk factors for
the development of RA, including reproductive factors such
as the use of oral contraceptives, hormone replacement
therapy, and breast feeding [15-17], and dietary factors such
as antioxidants [18,19], red meat protein [20,21], and fat
intake [22,23]. However, most of these have shown only
weak associations. Cigarette smoking is the only exposure
that has repeatedly been found to increase the risk of RA,
with a relative risk of about 1.8 [24-27].
Viruses and the development of RA
A viral trigger of RA in the genetically predisposed has been
hypothesized for many years [28-36]. A virus could act as an
adjuvant in the development of autoimmunity, non-specifically
stimulating innate immune responses, including mast cells,
dendritic cells, Toll-like receptors and complement receptors
[37]. Polyarthritis resembling RA is seen clinically soon after
exposure to multiple viruses including rubella, human T cell
leukemia virus-1 (HTLV-1), parvovirus B19, and hepatitis B
and C [36,38-40]. Exposure to a common virus would explain
the ubiquity of RA worldwide. However, such a virus has
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eluded identification by modern techniques possibly because
of a long latency period, with RA onset years after initial
exposure. Viruses including Epstein–Barr virus (EBV), parvo-
virus B19, HTLV-1, human herpesvirus-6, human herpesvirus-8,
and human endogenous retroviruses-5 have all been proposed
to be involved in the pathogenesis of RA [31-35,41-44].
However, most of the evidence implicating viruses in the
pathogenesis of RA is circumstantial and inconclusive.
Tantalizing observations have often been based on in vitro or
animal studies, case reports, or studies with small sample
sizes, cross-sectional designs, or no control groups.
Epstein–Barr virus
EBV, the causative agent of infectious mononucleosis, is a
DNA-containing herpesvirus that is extremely prevalent
worldwide, infecting more than 98% of the human population
by the age of 40 years [45]. It is highly associated with several
malignancies including nasopharyngeal carcinoma, Burkitt’s
lymphoma, T/NK cell lymphomas, lymphoproliferative disease
in immunocompromised hosts, and Hodgkin’s disease, in most
of which EBV genomes are detectable within tumor cells [45].
To initiate infection, EBV uses its major envelope glyco-
protein, gp350, to bind to its receptor, complement receptor-2,
on epithelial cells and B lymphocytes [46,47]. Major histo-
compatibility complex (MHC) class II molecules are cofactors
for the infection of B cells by EBV [48]. During initial infection
there is massive polyclonal expansion of B lymphocytes,
followed by that of CD8+ T lymphocytes in particular [49].
EBV then becomes latent within memory B lymphocytes and
persists for the lifetime of its human host. While it is latent
within the B cell, its viral genome is intact as an episome, but
most viral genes are not active [50]. The proteins it produces
are responsible for inhibiting apoptosis and blocking the
antiviral effects of interferon-γ on EBV-transformed B cells
[50,51]. EBV has multiple immunomodulating actions.
Binding of its major envelope glycoprotein gp350 to
complement receptor-2 leads to the upregulation of the
important inflammatory cytokines IL-1β, TNF-α, and IL-6 [52-
54]. EBV encodes an immunosuppressive viral IL-10 cytokine
and a viral colony-stimulating factor-1 cytokine receptor,
involved in its ability to escape immune detection [55-57]. B
cell transformation by EBV also induces the expression of
EBV-induced gene 3 (EBI3), which encodes a form of IL-12,
responsible for the initiation of Th1-type immunity [58-60].
The host’s cellular immune response has primary
responsibility for the control of latent EBV infection within the
B cells [49,50]. CD4+ T cells activate the innate immune
response to EBV and are required for the generation of
robust memory responses by CD8+ cells, which is important
in suppressing EBV [61-63]. EBV reactivation and EBV-
related lymphoproliferative diseases occur in immuno-
suppressed renal and bone marrow transplant patients [64]
and in association with HIV [65].
During late incubation and the early infectious phase of
mononucleosis, antibodies against EBV viral capsid antigen
(VCA) and early antigen complex – diffuse (EA-D) appear
[45,66]. Later, weeks to months after disease onset,
antibodies against EBV nuclear antigen (EBNA) and early
antigen complex – restricted (EA-R) emerge (Table 1)
[45,67]. Antibodies against EBNA-2 are detected first and
decline within a few weeks, followed by the rise of EBNA-1
antibodies, which normally persist at a stable level for life
[45,67]. Thus, in a normal adult, latent EBV infection is
associated with moderate, stable and highly correlated levels
of IgG antibodies against VCA, EBNA-1, and EA-R, with very
low or undetectable levels of antibodies against EBNA-2 and
EA-D [67-69].
In situations of decreased cellular immunity, however, EBV
reactivation, or the transition from latent to lytic infection, can
occur. Anti-VCA IgG antibodies, anti-EBNA-2 antibodies, and
anti-EA antibodies are often elevated in these situations,
which is consistent with EBV reactivation. The relationship
between EBV serologic responses and levels of viral
replication, as detected by polymerase chain reaction, is
variable [45,69]. Latent EBV can replicate and spread
despite the presence of antibodies, and antibody titers
correlate with viral activity rather than with the degree of
protection afforded [68]. In many diseases strongly
associated with EBV, such as nasopharyngeal carcinoma and
Burkitt’s lymphoma, anti-EBV serologies are abnormal many
years before the onset of disease. In nasopharyngeal
carcinoma, for example, levels of IgA anti-VCA antibody 10-
fold those in normal subjects are found years in advance of
the onset of disease [70], indicative of high levels of viral
replication. IgA anti-VCA antibody titers are used for
screening in Asia, where nasopharyngeal cancer is endemic
[71,72].
EBV and the pathogenesis of RA
In the quest to uncover an infectious trigger of RA, much
research has concentrated on the potential for molecular
mimicry presented by EBV. EBV was first implicated in the
pathogenesis of RA by Alspaugh and Tan [30,73], who
reported that sera from patients with RA were reactive
against a nuclear antigen in EBV-transformed lymphocytes.
This ‘RA nuclear antigen’ was determined as a glycine/
alanine-rich repeat in EBNA-1 [74,75]. Antibodies against
this repeat are cross-reactive with a 62 kDa protein present in
the synovium of patients with RA, but not in that of controls
[76-78]. Antigenic sequence similarities exist between other
EBV proteins and RA-specific proteins as well. These include
the EBV-encoded protein gp110, which has sequence
homology with the QKRAA amino acid motif (the ‘shared
epitope’) of the β-chain of human leukocyte antigen (HLA)-
DR4 [79,80]. Humans with EBV infection have antibodies
against the gp110 protein, as well as T cells with receptors
that recognize the QKRAA motif in both gp110 and HLA-
DR4 molecules. In addition, antibodies against EBV peptidePage 3 of 7
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p107, the major epitope of the EBV-encoded EBNA-1
antigen, recognize and bind to denatured collagen and
keratin [81]. These findings support the hypothesis that
molecular mimicry, either by influencing T cell receptor
recognition of the HLA ‘shared epitope’ or through the
production of autoantibodies against joint proteins, is
involved in RA disease pathogenesis.
Patients with existing RA have higher levels of antibodies
against several EBV-encoded proteins, including VCA [82],
early antigen (EA) [82], EBNA-1 [82-85], and EBNA-2 [86],
than do healthy controls, and the presence of RF does not
seem to be related to these elevations (Table 1). Patients
suffering from RA have a 10-fold increase in EBV DNA load in
peripheral blood mononuclear cells compared with that in
controls; this elevation is stable and not influenced by the
presence or absence of RF, age, duration of RA, disease
activity, or RA treatment [87]. Patients with RA have
significantly higher numbers of circulating EBV-infected B
cells [88] and EBV DNA loads in saliva [42]. Several studies
have shown that levels of EBV DNA and mRNA are much
higher in the synovium of patients with RA than in that of
healthy controls [83,89-91]. Synovial EBV DNA loads are
highest in patients with RA with at least one copy of the HLA-
DRB1 ‘shared epitope’, the strongest known genetic risk
factor for RA [89]. However, these cross-sectional findings
have never been tested in a prospective cohort with blood
drawn before the diagnosis of RA. Nevertheless, given the
ubiquity of the virus in the population, a binary assay for the
presence of anti-EBV antibodies years preceding the onset of
RA would be less informative than a sensitive titer
quantification compared with controls.
EBV-specific T cell function is also impaired in RA [92-98]. A
large proportion of the CD8+ T cells infiltrating rheumatoid
synovium recognize the EBV transactivating factors, BZLF-1
and BMLF-1, important in the control of EBV reactivation
[99]. The HLA-DR4 shared epitope, a strong genetic risk
factor for RA, is associated with low frequencies of T cells
specific for the EBV gp110 glycoprotein, also critical in the
control of EBV infection [98]. Clonal expansion of peripheral
CD8+ CD28– EBV-specific T cells is observed in patients
with RA but not in controls [100]. These cells are thought to
be dysfunctional, senescent suppressor T cells, possibly
caused by recurrent EBV stimulation and/or a primary defect
of T cell differentiation and proliferation in RA.
Antibodies directed against cyclic citrullinated peptides
(CCPs) are increasingly important in the early diagnosis of
RA [101,102]. Citrullination is the process of deimination of
peptidyl arginine to peptidyl citrulline, recognized specifically
by anti-CCP antibodies. These autoantibodies are directed
against citrullinated proteins in the rheumatoid synovium,
including fibrin, filaggrin, perinuclear factor, and keratin [103].
They are highly specific for RA (sensitivity 68%, specificity
98%) [101] and in prospective cohort studies are present
several years before the onset of RA [104-106]. Klareskog
and colleagues in Sweden have found that cigarette smoking
may trigger HLA-DR restricted immune reactions to
autoantigens modified by citrullination, potentially explaining
the interaction between HLA shared epitope and cigarette
smoking that greatly increases the risk of anti-CCP-positive
RA (L Klareskog, personal communication). Although it has
not yet been studied in relation to the citrullination of
autoantigens or the formation of autoantibodies, EBV could
potentially have a similar role. Moreover, the regulation of B
cell apoptosis might be important in the production of anti-
CCP antibodies [107]; EBV persists indefinitely in host B
cells and encodes at least two proteins that interfere with
apoptosis, namely BHFR1 (a viral homologue of the anti-
apoptotic protein Bcl-2) [108] and LMP-1 (latent membrane
protein-1) [109].
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Table 1
Patterns of anti-Epstein–Barr virus (EBV) serologies observed in different disease states
Disease state VCA EBNA-1 EBNA-2 EA References
Early, acute primary EBV infection IgA, IgM Undetectable ↑↑ EA-D [45,66]
Primary infection (weeks to months) IgG ↑↓ EA-R [45,67]
Latent EBV infection in healthy host Stable IgG Stable ↓ Stable EA-R [67]
Reactivation/EBV replication ↑↑ IgG ↑↑ ↑ ↑ [67-69,117]
Nasopharyngeal carcinomaa ↑↑ IgG, IgA ↑ IgG, IgA [70,118-120]
Burkitt’s lymphomaa ↑↑ IgG ↑↑ ↑↑ [70,121]
Multiple sclerosisa ↑↑ ↑ ↑ ↑ [111,112]
Systemic lupus erythematosusa ↑↑ [113,114]
Rheumatoid arthritis ↑↑↑↑ [82-86,122]
EA, EBV early antigen; EA-D, EBV early antigen – diffuse; EA-R, EBV early antigen – restricted; EBNA, EBV nuclear antigen; VCA, EBV viral capsid
antigen. aAbnormalities observed before disease onset.Chicken or egg?
Although the observations noted above support an association
between EBV, or the host’s immune response to it, and RA,
this association need not be causative. Elevated anti-EBV
antibody titers have also been found in other autoimmune
diseases, including Sjögren’s syndrome [110], and years
before the onset of both multiple sclerosis [111,112] and
systemic lupus erythematosus (SLE) [113,114]. Anti-EBV
antibody titers rise gradually from their first detectable levels
years before the first symptoms of SLE until the time of SLE
diagnosis, paralleling, and in some cases preceding, the
development of SLE-specific antibodies [113,114].
Whether the observed abnormalities in EBV-directed immune
responses and EBV viral loads are a cause or a consequence
of RA remains a mystery. Through its potential for molecular
mimicry, by polyclonal activation of B cells, or via some other
mechanism, EBV or an EBV-specific immune response could
be a trigger for the development of RA in the genetically
predisposed. Alternatively, an innate or acquired immune
defect in those with or at risk for RA could handicap the
host’s ability to suppress this chronic viral infection. There is
mounting evidence that patients with lupus, for example, have
impaired EBV-specific immune responses [115] and the
frequency of EBV-infected cells in the blood of patients with
SLE increases during SLE disease flares, independently of
immunosuppressive therapy and in concert with aberrant
expression of viral proteins [116]. This suggests that in those
with SLE, and perhaps similarly in those with RA, T cell
control of latent EBV infection is defective. Whether the virus
actually has an etiologic role in these autoimmune diseases,
or whether underlying immune abnormalities allow
dysregulation of latent EBV as an epiphenomenon, is the crux
of the matter.
Conclusion
The cause of RA, a highly disabling systemic autoimmune
disease, remains unknown. Family studies and genome-wide
scans have shown that there is an important genetic influence
in the susceptibility to RA; evidence points to a common
virus, such as EBV, that could act as a trigger in genetically
susceptible hosts. So far, studies looking for an association
between EBV infection and RA have been characterized by
small numbers and retrospective or cross-sectional designs.
Patients with established RA seem to have elevated levels of
anti-EBV antibodies and viral loads. These study designs
have not been able to address the timing of these
abnormalities with regard to the development of RA, nor have
they been able to exclude the possibility that RA itself, or its
treatment, is responsible for abnormally elevated EBV
serologic responses and viral loads. Understanding the timing
and directionality of the EBV–RA relationship is crucial to
distinguishing inciting from secondary events in RA
pathogenesis and to advancing our understanding of the
etiology of RA.
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